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Abstract
Background: Duodenal intraepithelial lymphocytosis (DIL) is a histological finding characterized by the increase of intrae-
pithelial CD3T-lymphocytes over the normal value without villous atrophy, mostly associated to coeliac disease (CD),
Helicobacter pylori (Hp) gastritis and autoimmune diseases.
Objective: To assess the occurrence of DIL, CD and Hp gastritis in an endoscopic population over a 13 year period.
Methods: From 2003 to 2015 we included adult patients who consecutively underwent oesophago-gastro-duodenoscopy
(OGD) with duodenal biopsies assessing the overall and annual occurrence of DIL and CD and the prevalence of Hp gastritis.
Results: 160 (2.3%) patients with DIL and 275 (3.9%) with CD were detected among 7001 patients. CD occurrence was higher
from 2003 to 2011, while since 2012 DIL occurrence gradually increased significantly compared to CD (p¼ 0.03). DIL patients
were more frequently female (p¼ 0.0006) and underwent OGD more frequently for dyspepsia (p¼ 0.002) and for indications
not related to gastrointestinal symptoms than CD patients (p¼ 0.0003). Hp gastritis occurred similarly in CD and DIL patients
but the latter had higher frequency of atrophic body gastritis (p¼ 0.005).
Conclusions: DIL is a condition increasing in the general endoscopic population mainly diagnosed by chance. Concomitant
gastric histological evaluation is able in one third of DIL patients to identify associated possible causes of DIL, such as Hp and
atrophic gastritis.
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Introduction
Duodenal intraepithelial lymphocytosis (DIL) is a
histological finding characterized by the increase of
intraepithelial CD3 T-lymphocytes (IEL) over the
normal value of 25–30/100 epithelial cells with pre-
served intestinal villous structure. Clinically, this con-
dition may be associated with symptomatic
malabsorption or more subtle micronutrient deficien-
cies related to specific or non-specific gastrointestinal
(GI) symptoms, as recently stated in a Consensus
Conference.1
DIL is commonly associated to a number of condi-
tions involving the GI tract or due to systemic disease
(non-GI diseases).2 Among GI diseases, DIL is mostly
associated to gluten-related disorders, such as coeliac
disease (CD) but also, more recently, non-coeliac gluten
sensitivity.1–4 Clinical studies demonstrated that DIL is
related to a final diagnosis of CD in a varying percent-
age (9–40%) of patients.3,5,6 Other non-gluten related
conditions associated to DIL are Helicobacter pylori
(Hp) gastritis,7,8 autoimmune disorders,9 drugs
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(non-steroidal anti-inflammatory agents, angiotensin II
receptor antagonists and proton-pump inhibitors),10,11
bacterial overgrowth,4 inflammatory bowel diseases,12
parasitic infestations,13 food allergies, typically for
cow’s milk and eggs,2 and immunodeficiency states
(e.g. common variable immune deficiency).14
Reported prevalence of DIL is very heterogeneous,
ranging from 1.3% in the general population up to
14.3% in a selected population.5,6,15,16 In the last
decade, the frequency of this histological entity seems
to have increased, reaching 7%, as reported in an endo-
scopic population.16
Hp infection is frequently associated to DIL, and its
diagnosis and treatment may lead to normalization of
duodenal IEL.7,8 Despite this strong relationship,
accurate histological data on the frequency of Hp infec-
tion in patients with DIL are lacking. Most of the
previous studies used a C13-urea breath test or non-
standardized gastric sampling biopsies to detect Hp
infection.4,8,10
The aim of this study was to assess the occurrence of
DIL, CD and Hp-related conditions in an endoscopic
population over a 13 year period.
Materials and methods
Study population
From January 2003 to December 2015 we evaluated in
the Sant’Andrea Hospital pathology database for
patients aged> 18 years who consecutively underwent
oesophago-gastro-duodenoscopy (OGD) with duo-
denal biopsies. Among these patients, we considered
those with a new diagnosis of DIL and CD. If some
patients, during the studied period, did more than one
gastroscopic procedure only the first one has been con-
sidered. We excluded from this population patients
with previous intestinal resection (e.g. bariatric surgery)
and/or bacterial overgrowth. The overall and annual
occurrence of diagnosis of DIL and CD was assessed.
Moreover in patients in whom besides duodenal biop-
sies also gastric biopsies were available, we assessed the
presence of Hp infection and related gastric histological
alterations both in DIL and CD patients (Figure 1).
All patients underwent an OGD using a flexible
video-gastroscope, with at least four biopsies taken
from the second part of the duodenum. Patients with
gastric biopsies had at least five biopsies (3 from the
antrum and 2 from the body) according to the updated
Sydney system.17 We excluded 10 DIL patients and 20
CD patients with only duodenal and antral biopsies, 3
DIL patients and 7 CD patients with biopsies only from
duodenum and body and 2 DIL patients and 3 CD
patients with biopsies only from the duodenum.
Histological evaluation
The histological samples were evaluated by a GI-dedi-
cated expert pathologist (EP). CD was diagnosed when
duodenal biopsy samples showed intestinal villous atro-
phy (mild, moderate or severe) with crypt hyperplasia
and intraepithelial lymphocytosis, according to the
Marsh/Oberhuber classification,18,19 and previously
described.20 Normal villous architecture and> 30
intraepithelial lymphocytes\100 enterocytes was defined
as DIL, according to Veress et al.21
Intraepithelial lymphocytes T count was expressed
as number of intraepithelial lymphocytes/100 epithelial
cells and was carried out on immunohistochemical
stained sections. Briefly, from a formalin-fixed,
7,001 pts with OGD and duodenal biopsies
275 (3.9%) pts with atrophic CD 160 (2.3%) pts with DIL
245 (89%) pts
gastric biopsies available
145 (90.6%) pts
gastric biopsies available
6,566 (93.8%) pts with normal
duodenal histology
Figure 1. Flowchart of study population.
CD¼ celiac disease; DIL¼ duodenal intraepithelial lymphocytosis; OGD¼ oesophago-gastro-duodenoscopy.
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paraffin-embedded 3 mm tissue sections were stained
with anti-CD3 mouse monoclonal antibody, clone
F7.2.38 (Dako, Glostrup, Denmark), after antigen
retrieval with EDTA at pH 9. Staining was visualized
by Envision-Flex in automated stainer (Dako,
Glostrup, Denmark).
Figure 2 presents histological pictures in Haematoxylin
& Eosin (H&E) and CD3 immunohistochemistry of DIL
and in H&E of atrophic CD (Marsh 3C).
Gastric histologic evaluation was performed accord-
ing to the updated Sydney System classification.17
Gastric specimens were considered to be Hp negative
if Hp was not detected with haematoxylin and eosin
staining. Chronic active gastritis was defined as the
presence of polymorphonuclear cells in the lamina pro-
pria in the absence of Hp organism. Chronic inactive
gastritis was defined as the presence of lymphocytes and
plasma cells within the lamina propria, in the absence
of activity or Hp organism.22 Reactive gastritis includes
foveolar or regenerative hyperplasia, oedema or hyper-
aemia of the lamina propria, erosions and smooth
muscle proliferation.23 Lymphocytic gastritis was
defined by the presence of at least 25 lymphocytes/100
epithelial cells on the surface and foveolar epithelium,
with chronic inflammation also in the lamina propria.24
Atrophy of the corporal mucosa was defined as the
focal or complete replacement of oxyntic glands by
metaplastic pyloric or intestinal glands, atrophy of the
antral mucosa was defined as focal or complete replace-
ment of antral glands by intestinal metaplastic
epithelium.25
Statistics
Data were expressed as values and percentages or med-
ians and interquartile ranges. Comparisons between
different groups were made using the Fisher’s exact
test or chi-square test. A p value <0.05 was considered
statistically signiEcant. Dedicated software (Medcalc
Belgium 12.0) was used for these purposes.
Results
From January 2003 to December 2015, 7001 patients
were identified over a 13 year period (Figure 1). DIL
was diagnosed in 160 patients and CD in 275 patients
with an overall occurrence of 2.3% and 3.9%, respect-
ively. Figure 3 shows the yearly occurrence of the new
diagnoses of DIL and CD during the study period. The
number of patients enrolled each year remained almost
Figure 2. Series of histological slides of typical mucosal biopsies in (a) DIL at H&E stain (10), (b) DIL at CD3 immunohistochemistry
(10), (c) Marsh 3C lesion at H&E (10).
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steady during the entire time-period, with minimal fluc-
tuations. Compared to DIL, the yearly occurrence of
CD was higher in the years from 2003 to 2011. Since
2012 the number of patients diagnosed with DIL has
increased, while the occurrence of new cases of CD has
decreased. We observed a statistically significant higher
occurrence (p¼ 0.001) of CD from 2003 to 2004 and
from 2008 to 2011. From 2005 to 2007, the number of
newly diagnosed cases of CD was higher than the
number of DIL, but did not reach statistical signifi-
cance (p¼ 0.5). Starting from 2012, the number of
patients newly diagnosed with DIL was higher com-
pared to those diagnosed with CD (p¼ 0.03).
Concerning patients’ clinical features (Table 1), a
significantly higher prevalence of females was observed
both in DIL (87.5%) and CD (73.2%) compared with
the endoscopic population with normal duodenal hist-
ology (66.5%) (p< 0.001 and p¼ 0.01, respectively).
Moreover, female gender was more frequent in patients
with DIL than in patients with CD (87.5% versus
73.2%) (p¼ 0.0006). The endoscopic population with
normal duodenal histology was significantly older of
age compared to both DIL and CD patients
(p¼ 0.001). DIL patients were older of age (40.5 yrs,
range 18–80) than CD patients (37 yrs, range 18–78;
p¼ 0.007). As shown in Table 1, DIL patients
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Figure 3. Yearly occurrence of duodenal intraepithelial lymphocytosis (DIL) and celiac disease (CD) over the 13-year study period.
Continuous line¼ celiac disease; dotted line¼ duodenal intraepithelial lymphocytosis.
*p< 0.05.
Table 1. Clinical features of patients with duodenal intraepithelial lymphocytosis (DIL) and celiac disease (CD).
DIL
n¼ 160
CD
n¼ 275 p
Female gender 140 (87.5%) 202 (73.2%) <0.001
Age, median (range) 40.5 (18–80) 37 (18–78) 0.007
Indications for oesophago-gastro-duodenoscopy
- Gastrointestinal symptoms (diarrhoea, abdominal pain) 21 (13%) 36 (13%) Ns
- Iron deficiency anaemia 64 (40%) 87 (31.6%) Ns
- Dyspepsia 33 (20.6%) 34 (12.3%) 0.02
- 1st degree family history for CD/ autoimmunity screening 6 (3.7%) 21 (7.6%) Ns
- By chance (others indications not related to gastrointestinal symptoms) 18 (11.5%) 7 (2.5%) <0.001
- Suspected CD (antibodies positivity, osteopenia, signs of malabsorption) 18 (11.2%) 90 (33%) <0.001
Data expressed as total number (percentage, %), when not otherwise indicated.
Ns¼ not significant.
814 United European Gastroenterology Journal 5(6)
underwent OGD more frequently for dyspepsia than
CD patients (p¼ 0.002). DIL patients were more fre-
quently diagnosed by indications to gastroscopy not
related to GI symptoms than CD patients
(p¼ 0.0003). As expected, signs of malabsorption, anti-
bodies positivity or osteopenia/osteoporosis with a
stronger suspicion for CD leaded more frequently to
CD diagnosis (p< 0.0001).
Gastric histology in DIL and CD patients
As shown in Table 2, atrophic gastritis, both auto-
immune and Hp-related, was found in 10 (6.9%)
patients with DIL and 3 (1.2%) patients with CD
(p¼ 0.005). Other gastric histological findings were
not statistically different between DIL and CD, as
normal gastric histology (42.7% vs 51%; p¼ 0.1173),
Hp-positive gastritis (26.9% vs 22%, respectively;
p¼ 0.325), Hp-negative gastritis (both chronic active
and inactive gastritis) (17.2% vs 13.5%; p¼ 0.377),
reactive gastritis (4.1% vs 9.4%; p¼ 0.071) and
lymphocytic gastritis (2% vs 2.8%; p¼ 0.750).
Discussion
This study assessed the occurrence of newly diagnosed
cases of DIL and CD in an endoscopic population over
a period of 13 years, showing an occurrence of 2.3% for
DIL and 3.9% for CD. The respective occurrence chan-
ged over time: CD had the highest occurrence from
2003 to 2011, but from 2012 to 2015 DIL was diag-
nosed more frequently exceeding CD. Several studies
evaluated the frequency of the DIL diagnosis leading
to heterogeneous results. The frequency of newly diag-
nosed cases of DIL ranged from 1.34% to 14.3%.5,15
Such different results may arise from different inclusion
criteria and time periods of the study population taken
into account. However, it has been recently reported
that the number of patients diagnosed with DIL is
increasing.16,26 One of the reasons for such increase
can be found in the expertise of the pathologists, who
make use of the immunohistochemical stain for
CD3þ lymphocytes. Another possible reason is the
spread of the conditions which may lead to DIL, such
as the chronic use of drugs or autoimmune diseases.4
But, the increase in newly diagnosed cases of DIL could
be also explained by the reduction, compared to the
past, in the number of IELs necessary for the diagnosis
(25–30 IELs/100 enterocytes nowadays, while in the
past the number of IELs to make diagnosis of DIL
was 40).
In our study, we considered patients regardless of
the indications for OGD. Although our unit is a ter-
tiary academic centre, patients were not selected on the
basis of indications for gastroscopy with high suspicion
for CD. Furthermore, our cut-off to diagnose DIL (30
IELs/100 enterocytes) was maintained steady over the
years thus avoiding the bias related to changed diag-
nostic criteria. Thus the findings of our study support
the previously reported increase in DIL diagnosis.
Our study showed that patients with DIL and CD
were mostly female and younger than patients with
normal histological duodenum. The increased preva-
lence of female patients with DIL and CD has already
been demonstrated by several studies,4,8,16,27 but there
are still no data available in literature on the compari-
son between DIL and CD patients in terms of age and
gender. In our study, we found that patients with DIL
are more frequently female and older than CD patients.
It has already been demonstrated in literature that
female gender has a higher predisposition to auto-
immune diseases, as autoimmune thyroid disease,
rheumatoid arthritis or ankylosing spondylitis,28 condi-
tions which are more frequently associated with DIL.
Some of these conditions are linked to chronic pain
requiring chronic use of analgesic drugs as NSAIDs,29
in turn related to DIL. Thus, it is possible that some
factors related with DIL are more frequent in females.
However, in general, the health-seeking behaviour and
the attitude of seeking medical attention are more pro-
nounced in females,30 possibly explaining the higher
female prevalence amongst DIL and CD.
In this study, we also evaluated the indications to
OGD for patients with DIL and CD. Table 1 shows
that the indications are different between the two
Table 2. Histological gastric mucosal findings in patients with
duodenal intraepithelial lymphocytosis (DIL) and celiac disease
(CD).
DIL
n¼ 145
CD
n¼ 245 p
Histologically normal
gastric mucosa
62 (42.7%) 125 (51%) Ns
Hp-related gastritis 39 (26.9%) 54 (22%) Ns
– Antral gastritis 6 12
– Pangastritis 33 42
Negative Hp gastritis 25 (17.2%) 33 (13.5%) Ns
– Chronic active gastritis 3 (2%) 7 (2.8%)
– Chronic inactive gastritis 22 (15.2%) 26 (10.7%)
Patients with reactive gastritis 6 (4.1%) 23 (9.4%) Ns
Atrophic gastritis 10 (6.9%) 3 (1.2 %) 0.005
– Hp-related 3 1
– Autoimmune 7 2
Lymphocytic gastritis 3 (2%) 7 (2.8%) Ns
Data expressed as total number (percentage, %).
Hp¼Helicobacter pylori.
Ns¼ not significant.
Galli et al. 815
groups. On the one hand, patients with DIL were more
often diagnosed when they underwent OGD for non-
specific symptoms, such as dyspepsia, or for other rea-
sons not related to GI symptoms (i.e. family history of
gastric cancer or thoracic pain). On the other hand,
patients with CD were more often diagnosed by per-
forming OGD for the common signs and symptoms
suggestive of CD (i.e. malabsorption, diarrhoea,
abdominal pain), as also shown by a very recent
study reporting that patients with typical GI symptoms
are more easily diagnosed as having CD disease.31
There are few studies on the evaluation of the indica-
tions to OGD and only two of them showed that dys-
pepsia is a common indication for OGD for those
patients who are diagnosed with DIL.8,16 Moreover, a
recent study showed that dyspepsia is more severe in
patients with Hp infection who have also DIL.32 The
same study also showed that dyspepsia may disappear
or be significantly reduced after Hp eradication. This
could suggest that duodenal biopsies should be taken,
together with gastric biopsies, in patients who undergo
OGD for gastric symptoms in order to exclude the pres-
ence of DIL.
With respect to the gastric histologic alterations
related to DIL and CD, our study showed some pecu-
liarities. First of all, the prevalence of Hp infection in
patients with DIL and CD was not statistically different
(26.9% versus 22%). Compared to the frequency of Hp
infection in the Italian general population in an area
where the infection has a medium to high prevalence,33
this figure is not different to that shown in the two
groups of patients considered in our study. It has
been described that Hp infection leads to DIL in a per-
centage of patients ranging from 6% to 14%, however
the prevalence of such infection in DIL patients is still
not clear.4,16,34 Only one study described a Hp preva-
lence of 19% in patients with DIL, a lower prevalence
with respect to the local general population.35 This lack
of data is most likely related to the fact that Hp infec-
tion is usually evaluated through C13 urea breath test or
incomplete gastric biopsies (that is not taken from both
gastric body and antrum, according to the updated
Sydney System),4,8,10 which do not allow to assess the
real prevalence of Hp infection. In our study, we
enrolled only patients who had complete gastric biop-
sies in order to obtain an accurate evaluation of Hp
infection prevalence in DIL patients, which was
26.9%. According to these results, eradication therapy
for Hp should be administered in DIL patients, in order
to tempt to obtain the regression of the histological
alterations, both in the stomach and in duodenum.
With respect to the gastric histologic alterations not
related to Hp infection, our study showed that 17.2%
of DIL patients and 13.5% of CD patients had Hp
negative gastritis (both chronic active and inactive
gastritis). In particular, the percentage of patients
with DIL who had chronic inactive gastritis was
higher than the percentage showed by the study of
Lebwohl et al.36 Such data may be related to geograph-
ical differences between the populations considered in
the two studies. Moreover, so far, no study has been
carried out to evaluate the possible role of this condi-
tion as a cause of DIL.
With regard to lymphocytic gastritis, there is only
one study that evaluated the prevalence of such a con-
dition in DIL.36 Consistent with that study, in our
population the prevalence was low in patients with
DIL (Table 2). We also observed that lymphocytic gas-
tritis was lower among our CD patients compared to
what has been observed before.36–38 This might be
explained, again, by geographical and ethnic differences
between the study populations.
Our study also showed that 6.9% of DIL patients
had AG (atrophic gastritis of body and fundus), com-
pared to 1.2% of CD patients. Our study is the first one
to show a higher prevalence of AG in DIL patients
compared to CD patients. This different AG occurrence
in DIL patients may be explained by two pathogenic
mechanisms, which are responsible for the gastric atro-
phy and which could lead to an increase in the number
of IELs: autoimmunity and Hp infection.39 In our
patients, AG seemed to arise from both the described
pathogenic mechanisms (Table 2) and for such reason it
is likely that the prevalence of AG is higher in DIL
patients rather than CD patients. Therefore, a complete
and accurate gastric mapping is useful to detect AG in
DIL patients.
In conclusion, our study showed that DIL is increas-
ing in the endoscopic population and that it is more
frequently found in patients who undergo OGD for
dyspeptic symptoms or for others indications not
related to GI symptoms. Moreover, our study showed
that the concomitant gastric histological evaluation is
able, in one third of DIL patients, to identify associated
possible causes of DIL, such as Hp and atrophic
gastritis.
Declaration of conflicting interests
None declared.
Funding
This work was supported via grants from University
Sapienza, Rome, in 2016.
References
1. Rostami K, Aldulami D, Holmes G, et al. Microscopic
enteritis: Bucharest consensus. World J Gastroenterol
2015; 21: 2593–2604.
816 United European Gastroenterology Journal 5(6)
2. Brown I, Mino-Kenudson M, Deshpande V, et al.
Intraepithelial lymphocytosis in architecturally preserved
proximal small intestinal mucosa: an increasing diagnos-
tic problem with a wide differential diagnosis. Arch
Pathol Lab Med 2006; 130: 1020–1025.
3. Wahab PJ, Crusius JB, Meijer JW, et al. Gluten challenge
in borderline gluten-sensitive enteropathy. Am J
Gastroenterol 2001; 96: 1464–1469.
4. Aziz I, Evans KE, Hopper AD, et al. A prospective study
into the aetiology of lymphocytic duodenosis. Aliment
Pharmacol Ther 2010; 32: 1392–1397.
5. Kakar S, Nehra V, Murray JA, et al. Significance of
intraepithelial lymphocytosis in small bowel biopsy sam-
ples with normal mucosal architecture. Am J
Gastroenterol 2003; 98: 2027–2033.
6. Mahadeva S, Wyatt JL and Howdle PD. Is a raised
intraephitelial lymphocyte count with normal duodenal
villous architecture clinically relevant? J Clin Pathol
2002; 55: 424–428.
7. Memeo L, Jhang J, Hibshoosh H, et al. Duodenal intrae-
pithelial lymphocytosis with normal villous architecture:
common occurrence in H. pylori gastritis. Mod Pathol
2005; 18: 1134–1144.
8. Nahon S, Patey-Mariaud De Serre N, Lejeune O, et al.
Duodenal intraepithelial lymphocytosis during
Helicobacter pylori infection is reduced by antibiotic
treatment. Histopathology 2006; 48: 417–423.
9. Gentile NM, Murray JA and Pardi DS. Autoimmune
enteropathy: a review and update of clinical management.
Curr Gastroenterol Rep 2012; 14: 380–385.
10. Rosinach M, Esteve M, Gonzalez C, et al. Lymphocytic
duodenosis: aetiology and long-term response to specific
treatment. Dig Liver Dis 2012; 44: 643–648.
11. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al.
Severe sprue-like enteropathy associated with olmesartan.
Mayo Clin Proc 2012; 87: 732–738.
12. Vidali F, Di Sabatino A, Broglia F, et al. Increased
CD8þ intraepithelial lymphocyte infiltration and
reduced surface area to volume ratio in duodenum of
patients with ulcerative colitis. Scand J Gastroenterol
2010; 45: 684–689.
13. Hanevik K, Hausken T, Morken MH, et al. Persisting
symptoms and duodenal inflammation related to
Giardia duodenalis infection. J Infect 2007; 55: 524–530.
14. Washington K, Stenzel TT, Buckley RH, et al.
Gastrointestinal pathology in patients with common vari-
able immunodeficiency and X linked agammaglobulin-
aemia. Am J Surg Pathol 1996; 20: 1240–1252.
15. Biagi F, Bianchi I, Campanella J, et al. The prevalence
and the causes of minimal intestinal lesions in patients
complaining of symptoms suggestive of enteropathy: a
follow-up study. J Clin Pathol 2008; 61: 1116–1118.
16. Shmidt E, Smyrk TC, Boswell CL, et al. Increasing duo-
denal intraepithelial lymphocytosis found at upper endos-
copy: time trends and associations. Gastrointest Endosc
2014; 80: 105–111.
17. Dixon MF, Genta RM, Yardley JH, et al. Classification
and grading of gastritis. The updated Sydney system. Am
J Surg Pathol 1996; 20: 1161–1181.
18. Marsh MN. Gluten, major histocompatibility complex,
and the small intestine. A molecular and immunobiologic
approach to the spectrum of gluten sensitivity (‘celiac
sprue’). Gastroenterology 1992; 102: 330–354.
19. Villanacci V, Ceppa P, Tavani E, et al. Coeliac disease:
the histology report. Dig Liver Dis 2011; 43(Suppl 4):
S385–S395.
20. Galli G, Esposito G, Lahner E, et al. Histological recov-
ery and gluten-free diet adherence: a prospective 1-year
follow-up study of adult patients with coeliac disease.
Aliment Pharmacol Ther 2014; 40: 639–647.
21. Veress B, Franze`n L, Bodin L, et al. Duodenal intrae-
pithelial lymphocyte-count revisited. Scand J
Gastroenterol 2004; 39: 138–144.
22. Genta RM and Sonnenberg A. Helicobacter-negative
gastritis: a distinct entity unrelated to Helicobacter
pylori infection. Aliment Pharmacol Ther 2015; 41:
218–226.
23. Genta RM. Differential diagnosis of reactive gastropa-
thy. Semin Diagn Pathol 2005; 22: 273–283.
24. Carmack SW, Lash RH, Gulizia JM, et al. Lymphocytic
disorders of the gastrointestinal tract: a review for the
practicing pathologist. Adv Anat Pathol 2009; 16:
290–306.
25. Annibale B, Aprile MR, D’Ambra G, et al. Cure of
Helicobacter pylori infection in atrophic body gastritis
patients does not improve mucosal atrophy but reduces
hypergastrinemia and its related effects on body ECL-cell
hyperplasia. Aliment Pharmacol Ther 2000; 14: 625–634.
26. Lauwers GY, Fasano A and Brown I. Duodenal lympho-
cytosis with no or minimal enteropathy: much ado about
nothing? Mod Pathol 2015; 28(Suppl 1): S22–S29.
27. Zanini B, Lanzarotto F, Villanacci V, et al.
Clinical expression of lymphocytic duodenosis in
‘mild enteropathy’ celiac disease and in functional gastro-
intestinal syndromes. Scand J Gastroenterol 2014; 49:
794–800.
28. Fairweather D, Frisancho-Kiss S and Rose NR. Sex dif-
ferences in autoimmune disease from a pathological per-
spective. Am J Pathol 2008; 173: 600–609.
29. Atzeni F, Masala IF, Salaffi F, et al. Pain in systemic
inflammatory rheumatic diseases. Best Pract Res Clin
Rheumatol 2015; 29: 42–52.
30. Jørgensen JT, Andersen JS, Tjønneland A, et al.
Determinants related to gender differences in general
practice utilization: Danish diet, cancer and health
cohort. Scand J Prim Health Care 2016; 15: 1–10.
31. Roy A, Mehra S, Kelly CP, et al. The association between
socioeconomic status and the symptoms at diagnosis of
celiac disease: a retrospective cohort study. Ther Adv
Gastroenterol 2016; 9: 495–502.
32. Mirbagheri SA, Khajavirad N, Rakhshani N, et al.
Impact of Helicobacter pylori infection and microscopic
duodenal histopathological changes on clinical symptoms
of patients with functional dyspepsia. Dig Dis Sci 2012;
57: 967–972.
33. Lahner E, Zullo A, Hassan C, et al. Detection of gastric
precancerous conditions in daily clinical practice: a
nationwide survey. Helicobacter 2014; 19: 417–424.
Galli et al. 817
34. Hammer STG and Greenson JK. The clinical significance
of duodenal lymphocytosis with normal villus architec-
ture. Arch Pathol Lab Med 2013; 137: 1216–1219.
35. Simondi D, Ribaldone DG and Bonagura GA.
Helicobacter pylori in celiac disease and in duodenal
intraepithelial lymphocytosis: active protagonist or inno-
cent bystander? Clin Res Hepatol Gastroenterol 2015; 39:
740–745.
36. Lebwohl B, Green PH and Genta RM. The coeliac stom-
ach: gastritis in patients with coeliac disease. Aliment
Pharmacol Ther 2015; 42: 180–187.
37. Brown IS, Smith J and Rosty C. Gastrointestinal path-
ology in celiac disease: a case series of 150 consecutive
newly diagnosed patients. Am J Clin Pathol 2012; 138:
42–49.
38. Villanacci V, Bassotti G, Liserre B, et al. Helicobacter
pylori infection in patients with coeliac disease. Am J
Gastroenterol 2006; 101: 1880–1885.
39. Lahner E and Annibale B. Pernicious anemia: new
insights from a gastroenterological point of view. World
J Gastroenterol 2009; 15: 5121–5128.
818 United European Gastroenterology Journal 5(6)
